Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOMCAT: Trans-arterial treatment of intra-hepatic cholangiocarcinoma not amenable to resection
2023-504433-50-00Phase 4Authorised
- Sponsor
- Oslo University Hospital
- Start
- Nov 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of floxuridine, gemcitabine and oxaliplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Oslo University Hospital. Primary endpoint: Median survival time. Planned start Nov 2023; status: authorised.
02
Drugs
floxuridinegemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2023-504433-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504433-50-00.